Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL C UBA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578540860
CMS profile
206711
Location
FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,791.32

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,925.55 190
Travel and Lodging $1,865.77 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL C UBA

NPI 1578540860 · CMS profile ID 206711

Allopathic & Osteopathic Physicians / Internal Medicine

FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL C UBA, NPI 1578540860, CMS profile ID 206711. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL C UBA, NPI 1578540860, CMS profile ID 206711, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578540860?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $4,791.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exact Sciences Corporation $23.8505/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026510283 CMS
SANOFI-AVENTIS U.S. LLC $19.8505/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049898279 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.0205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000362679 CMS
Lilly USA, LLC $14.8305/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031433161 CMS
GlaxoSmithKline, LLC. $3.1105/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682263 CMS
Medtronic, Inc. $2.8005/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003153 CMS
Novo Nordisk Inc $16.4705/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171493 CMS
Scilex Pharmaceuticals Inc. $17.5805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045466859 CMS
AstraZeneca Pharmaceuticals LP $16.0405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015904657 CMS
Medtronic, Inc. $2.2705/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003171 CMS
Novo Nordisk Inc $12.5005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171329 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.7505/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057159631 CMS
Novo Nordisk Inc $17.5405/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171609 CMS
AstraZeneca Pharmaceuticals LP $17.5905/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016118661 CMS
Inspire Medical Systems, Inc. $21.2805/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058874359 CMS
AstraZeneca Pharmaceuticals LP $16.3304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015169767 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.9304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000307339 CMS
GlaxoSmithKline, LLC. $13.1604/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681467 CMS
GlaxoSmithKline, LLC. $16.9304/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681457 CMS
Exact Sciences Corporation $18.4104/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026510267 CMS
Novo Nordisk Inc $13.0404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171363 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.4004/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996990185 CMS
Lilly USA, LLC $9.3604/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031319965 CMS
AstraZeneca Pharmaceuticals LP $16.3704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016246559 CMS
Merck Sharp & Dohme LLC $16.2704/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048263511 CMS
Novo Nordisk Inc $16.6104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171552 CMS
Lilly USA, LLC $14.2204/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031448677 CMS
GlaxoSmithKline, LLC. $15.0504/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682301 CMS
Novo Nordisk Inc $16.6604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171585 CMS
Genentech USA, Inc. $0.9203/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336533 CMS
Genentech USA, Inc. $1.3403/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336513 CMS
Genentech, Inc. $82.8703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336539 CMS
Genentech USA, Inc. $907.7003/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336517 CMS
Genentech USA, Inc. $856.5403/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336523 CMS
Genentech USA, Inc. $1.1203/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336527 CMS
Medtronic, Inc. $3.3703/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003145 CMS
Medtronic, Inc. $3.6703/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003137 CMS
Medtronic, Inc. $73.8503/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026003129 CMS
Novo Nordisk Inc $19.7003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171653 CMS
GlaxoSmithKline, LLC. $6.1003/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001681475 CMS
GlaxoSmithKline, LLC. $9.7903/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682225 CMS
GlaxoSmithKline, LLC. $15.0503/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001682567 CMS
Lilly USA, LLC $0.5803/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031324791 CMS
Lilly USA, LLC $13.4803/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031353427 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.0003/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000342213 CMS
Exact Sciences Corporation $24.8803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026510255 CMS
Novo Nordisk Inc $14.5803/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001171423 CMS
Scilex Pharmaceuticals Inc. $23.5203/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045451597 CMS
Bayer Healthcare Pharmaceuticals Inc. $18.8803/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000306651 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.0703/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996990189 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,677.51 219
PY2020 $1,953.22 139
PY2021 $2,950.48 205
PY2022 $2,953.01 168
PY2023 $4,791.32 193
PY2024 $3,045.02 117
PY2025 $2,072.54 122

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $678,672.13 11
PY2024 Recipient $99,780.00 1
PY2024 Principal investigator $372,920.00 13
PY2023 Principal investigator $18,987.84 5
PY2022 Principal investigator $7,788.32 4
PY2021 Principal investigator $2,970.75 7
PY2020 Principal investigator $7,452.25 7
PY2019 Principal investigator $55,394.72 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $870.52 09/04/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES No dispute reported 06/30/2026 1187878569
Principal investigator 1 Eli Lilly and Company $170,084.00 08/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187876515
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878383
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $4,545.23 04/24/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 No dispute reported 06/30/2026 1187877205
Principal investigator 1 Eli Lilly and Company $339.50 03/26/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880543
Principal investigator 1 Eli Lilly and Company $8,432.94 02/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876747
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187890980
Principal investigator 1 Eli Lilly and Company $10,324.96 01/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877277
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,749.99 01/15/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185541048
Principal investigator 1 Eli Lilly and Company $49,590.99 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878357
Principal investigator 1 Eli Lilly and Company $415,164.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882742